trabikibart (CSL311) / CSL Behring 
Welcome,         Profile    Billing    Logout  

1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
trabikibart (CSL311) / CSL Behring
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

Completed
1
78
Europe
Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo
CSL Behring
Asthma
11/23
11/23

Download Options